X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PT-112 is first small-molecule conjugate of pyrophosphate in oncology and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death, that bind to dendritic cells and lead to downstream immune effector cell recruitment in tumor microenvironment.
Lead Product(s): Imifoplatin
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022
Details:
PT-112 is first small-molecule conjugate of pyrophosphate in oncology possesses unique pleiotropic mechanism of action promotes immunogenic cell death, induce potent mitochondrial stress and immunogenic cell death in human prostate cancer cell lines.
Lead Product(s): Imifoplatin,Avelumab
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
PT-112, a novel small molecule conjugate of pyrophosphate with a pleiotropic mechanism of action that promotes immunogenic cell death (ICD) in the tumor microenvironment.
Lead Product(s): Imifoplatin
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
Details:
Data on multi-center dose escalation study of PT-112 in multiple myeloma patients will be presented. PT-112 is a novel small molecule conjugate of pyrophosphate having a unique pleiotropic mechanism of action that promotes immunogenic cell death, through the release of DAMPs.
Lead Product(s): Imifoplatin
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
PT-112's selectivity to glycolysis-dependent cells over those able to conduct aerobic respiration, and its initiation of autophagy, are promising mechanistic findings that tie in well with PT-112's ability to induce immunogenic cell death.
Lead Product(s): Imifoplatin
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
The purpose of the Phase 2 multi-center, open-label study is to confirm the appropriate dose level and to evaluate preliminary evidence of efficacy of PT-112 in late-line mCRPC patients.
Lead Product(s): Imifoplatin
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
Data revealing novel mechanistic attributes of its lead candidate PT-112, an immunogenic cell death inducer under Phase 2 development, will be presented at the 32nd Symposium of the EORTC, the National Cancer Institute and the American Association for Cancer Research (AACR).
Lead Product(s): Imifoplatin,Avelumab
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
The combination of PT-112 and avelumab was found to be safe and well tolerated in 36 heavily pre-treated solid tumor patients who have exhausted standard therapy options, the majority of whom had received prior immunotherapy.
Lead Product(s): Imifoplatin,Avelumab
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
New clinical data from a dose escalation study of lead candidate PT-112, an immunogenic cell death inducer, used in combination with PD-L1 checkpoint inhibitor avelumab, will be presented at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress.
Lead Product(s): Imifoplatin,Avelumab
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
The granted claims are directed to the use of (pyrophosphato)platinum(II) or (pyrophosphato)platinum(IV) complexes, inclusive of the Company's lead compound, PT-112, as therapeutic agents for the treatment of bone and blood cancers, such as multiple myeloma.
Lead Product(s): Imifoplatin
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
